Loading stock data…
$23.52
As of September 8, 2026, Cyclerion Therapeutics, Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $1.02M↑ | $875,000↑ | $93,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.77M↑ | -$3.21M↓ | -$838,000↑ | -$1.01M↑ | -$1.67M |
| Net Income | -$1.75M↑ | -$3.18M↓ | -$799,000↑ | -$976,000↓ | -$324,000 |
As of September 8, 2026, Cyclerion Therapeutics, Inc. was acquired by Korsana Biosciences, Inc. in a reverse merger transaction. Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases ...